Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
Spyre points to phase 2 win for ulcerative colitis drug as proof it could take on Takeda’s Entyvio
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.